CC
ATRA icon

Checkpoint Capital’s Atara Biotherapeutics ATRA Stock Holding History

Checkpoint Capital’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-35,714
Closed -$620K – 17
2024
Q1 		$620K Buy
+35,714
New +$634K 0.41% 17

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Checkpoint Capital's ATRA Position: Q2 2024 in Review

Checkpoint Capital sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 35,714 shares — an estimated $620K sold.

Checkpoint Capital first reported a position in ATRA in Q1 2024 and held it in 1 quarter. The position peaked at $620K in Q1 2024. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • Checkpoint Capital reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Checkpoint Capital sold 35,714 Atara Biotherapeutics shares in Q2 2024, an estimated $620K.
  • Checkpoint Capital first reported a position in Atara Biotherapeutics in Q1 2024 and held it in 1 quarter.
  • Checkpoint Capital's Atara Biotherapeutics position peaked at $620K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on Checkpoint Capital's 13F filing for Q2 2024, filed 14 Aug 2024.